Henry Schein Valuation
Is HSIC * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HSIC * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HSIC * (MX$1325) is trading below our estimate of fair value (MX$2564.06)
Significantly Below Fair Value: HSIC * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HSIC *?
Other financial metrics that can be useful for relative valuation.
What is HSIC *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$9.41b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.1x |
Enterprise Value/EBITDA | 14.3x |
PEG Ratio | 1.2x |
Price to Earnings Ratio vs Peers
How does HSIC *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 22.6x | ||
1099 Sinopharm Group | 6.9x | 6.8% | HK$67.4b |
601607 Shanghai Pharmaceuticals Holding | 17.5x | 19.0% | CN¥59.0b |
000963 Huadong Medicine | 20.2x | 2.0% | CN¥56.7b |
AMP Amplifon | 45.6x | 17.7% | €7.1b |
HSIC * Henry Schein | 22.6x | 18.4% | Mex$9.4b |
Price-To-Earnings vs Peers: HSIC * is expensive based on its Price-To-Earnings Ratio (22.6x) compared to the peer average (22.5x).
Price to Earnings Ratio vs Industry
How does HSIC *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: HSIC * is expensive based on its Price-To-Earnings Ratio (22.6x) compared to the Global Healthcare industry average (21.8x).
Price to Earnings Ratio vs Fair Ratio
What is HSIC *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 22.6x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HSIC *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.